Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2024-212052

Published: 2024

Journal Articles

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 346.

https://doi.org/10.1182/blood-2024-208106

Published: 2024

Journal Articles

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Blood (2023) 142 (Supplement 1): 3507.

https://doi.org/10.1182/blood-2023-187946

Published: 2023

Journal Articles

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 2232–2233.

https://doi.org/10.1182/blood-2022-160294

Published: 2022

Journal Articles

Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections

Rishab Prakash, James Long, Paul Edelkamp, Jr., Mark Knafl, Sairah Ahmed, Fareed Khawaja, Loretta J. Nastoupil, Joanna-Grace Manzano, Victor Mulanovich, Sabitha Prabhakaran, Andrew Futreal, Scott E Woodman, Swaminathan Padmanabhan Iyer

Blood (2022) 140 (Supplement 1): 10907–10908.

https://doi.org/10.1182/blood-2022-169853

Published: 2022

Journal Articles

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Blood (2022) 140 (16): 1753–1763.

https://doi.org/10.1182/blood.2021014956

Published: 2022

Includes: Supplemental data

Journal Articles

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood (2021) 138 (18): 1733–1739.

https://doi.org/10.1182/blood.2020010483

Published: 2021

Includes: Supplemental data

Journal Articles

Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade

Sung-Eun Lee, MD PhD, Feng Wang, PhD, Abel Trujillo-Ocampo, PhDMS, Wilfredo Ruiz Vazquez, Hyun-Woo Cho, Koichi Takahashi, MD PhD, Gheath Alatrash, Jeffrey J. Molldrem, Richard E. Champlin, MD, Naval Daver, MD, Hagop M. Kantarjian, MD, P. Andrew Futreal, Guillermo Garcia-Manero, MD, Jin S. Im

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-136963

Published: 2020

Journal Articles

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-137335

Published: 2020

Journal Articles

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Yuya Sasaki, MDPhD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P Andrew Futreal, PhD, Feng Wang, PhD, Ken Furudate, DDM, PhD, Rebecca Garris, MSc, Koichi Takahashi, MD PhD, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136676

Published: 2020

Journal Articles

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137555

Published: 2020

Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 17.

https://doi.org/10.1182/blood-2019-122274

Published: 2019

Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2753.

https://doi.org/10.1182/blood-2019-122017

Published: 2019

Journal Articles

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Veronica A Guerra, MD, Yan Yuanqing, PhD, Joanne Hsu, BS, Feng Wang, PhD, Mansour Alfayez, MD, Kiyomi Morita, MD, Xingzhi Song, PhD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Guillermo Montalban Bravo, MD, Jianhua Zhang, PhD, Latasha Little, BS, Curtis Gumbs, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 458.

https://doi.org/10.1182/blood-2019-127498

Published: 2019

Journal Articles

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Ronald M. Paranal, MD, Hagop M. Kantarjian, MD, Alexandre Reuben, PhD, Celine Kerros, PhD, Priya Koppikar, PhD, Latasha Little, BS, Curtis Gumbs, Nicholas J. Short, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Jeffrey J. Molldrem, P. Andrew Futreal, PhD, Ghayas C. Issa, MD

Blood (2019) 134 (Supplement_1): 5186.

https://doi.org/10.1182/blood-2019-129911

Published: 2019

Journal Articles

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

Ghayas C. Issa, MD, Christopher B. Benton, MD, Vakul Mohanty, PhD, Yifei Shen, PhD, Zoe Alaniz, Feng Wang, PhD, P. Andrew Futreal, PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Nicholas Navin, PhD, Marina Y Konopleva, MD PhD, Ken Chen, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2717.

https://doi.org/10.1182/blood-2019-130540

Published: 2019

Journal Articles

PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

Tianyuan Hu, Kiyomi Morita, Matthew C. Hill, Yajian Jiang, Ayumi Kitano, Yusuke Saito, Feng Wang, Xizeng Mao, Kevin A. Hoegenauer, Kazuhiro Morishita, James F. Martin, P. Andrew Futreal, Koichi Takahashi, Daisuke Nakada

Blood (2019) 134 (7): 614–625.

https://doi.org/10.1182/blood.2018888255

Published: 2019

Includes: Supplemental data

Journal Articles

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Paolo Strati, MD, Koichi Takahashi, MD, Michael J. Keating, MD, Philip A. Thompson, MBBS, Christina Hinojosa, Diana Rodriguez, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Andrew Futreal, PhD, Alessandra Ferrajoli, MD

Blood (2018) 132 (Supplement 1): 295.

https://doi.org/10.1182/blood-2018-99-111488

Published: 2018

Journal Articles

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

Blood (2018) 132 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2018-99-116685

Published: 2018

Journal Articles

High Prevalence of PPM1D Mutations in Therapy-Related AML/MDS Is Due to Context-Specific Clonal Hematopoiesis

Joanne Hsu, BS, Tajhal Dayaram, Ayala Tovy, PhD, Etienne De Braekeleer, PhD MSc, Mira Jeong, PhD, Jason H. Rogers, MS, Feng Wang, PhD, Jianhua Zhang, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, George S. Vassiliou, Andrew Futreal, PhD, Lawrence Donehower, Koichi Takahashi, MD, Margaret Goodell, PhD

Blood (2018) 132 (Supplement 1): 746.

https://doi.org/10.1182/blood-2018-99-115007

Published: 2018

NARROW

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade

Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

High Prevalence of PPM1D Mutations in Therapy-Related AML/MDS Is Due to Context-Specific Clonal Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only